Nautilus Biotechnolgy (NAUT) Earnings Date & Reports

Key Takeaways

• Nautilus Biotechnology reported a third quarter 2026 net loss of $15.6 million, or $0.12 per share, beating the consensus estimate of a $0.14 per share loss.
• Revenue of $0.2 million modestly exceeded expectations, driven by its Iterative Mapping Early Access Program and grant funding from The Michael J. Fox Foundation.
• Operating expenses rose 10% year over year to $16.9 million, while the net loss widened from $13.6 million in the prior-year quarter.
• Management raised its full-year 2026 revenue outlook, now expecting total revenue to exceed its earlier guidance of approximately $0.5 million.
• The company ended the quarter with $114.3 million in cash, cash equivalents, and investments, supporting a runway it expects to extend into early 2028.
• Get more information about the ticker's Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
• Explore Trending AI Robots to see AI-powered trading strategies currently capturing market attention.

Earnings Context and Why It Matters

Nautilus Biotechnology is a development-stage life sciences company building the Voyager platform, a single-molecule proteomics system designed to quantify the proteome at unprecedented scale. Because the company is only just beginning to recognize revenue, this quarterly report matters less for near-term profitability and more for what it reveals about the pace of commercialization. Investors are watching whether early access customers validate the technology, how grant funding ramps, and whether the company can control cash burn while it works toward a commercial launch. With instrument pre-orders targeted for early 2027 and shipments expected in mid-2027, this quarter offered an important progress check on the path from research tool to commercial product.

Reported Results

For the third quarter ended September 30, 2026, Nautilus reported total revenue of $0.2 million, consisting primarily of grant revenue tied to its Michael J. Fox Foundation-funded alpha-synuclein assay work and service revenue from the Iterative Mapping Early Access Program. This figure slightly exceeded consensus estimates and marked a milestone as the company recognized its first revenue from both early access services and grant activity.

The company posted a net loss of $15.6 million, or $0.12 per share, compared with a net loss of $13.6 million, or $0.11 per share, in the same period last year. The reported loss per share came in ahead of the consensus estimate of a $0.14 loss. Operating expenses increased 10% year over year to $16.9 million, reflecting higher laboratory and professional services costs and increased salaries and related benefits, partially offset by lower facilities expenses.

Cash, cash equivalents, and investments totaled $114.3 million as of September 30, 2026, down from $129.2 million at the end of the second quarter, reflecting roughly $14.9 million in cash use during the period. On guidance, management now expects total 2026 revenue to exceed its prior outlook of approximately $0.5 million, with fourth quarter revenue expected to grow sequentially from the third quarter, excluding any potential contribution from its ARPA-H (Advanced Research Projects Agency for Health) funded SEEDS work.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors monitoring names like NAUT, the AI Screener offers a structured way to surface setups that match specific criteria and investment styles.

Market Reaction and Investor Sentiment

Despite the top- and bottom-line beat, shares of Nautilus Biotechnology declined sharply following the report, with the stock falling roughly 24.7% in the session. The move suggests investors focused less on the narrow earnings beat and more on the company's still-modest revenue scale, the year-over-year widening of its net loss, and rising operating expenses. Sentiment was also likely pressured by management's disclosure that it is exploring raising additional capital between now and mid-2027 to fund assay portfolio expansion, platform capabilities, and the build-out of its commercial team. For a pre-commercial company, execution milestones and cash position often carry more weight than a single quarter's loss, and the market's reaction reflects caution about the financing and timeline ahead of the Voyager launch.

Forward Outlook and Key Factors to Monitor

Looking ahead, the central catalyst for Nautilus is the commercial launch of the Voyager platform. Management expects to announce the launch and open pre-orders in early 2027, with instrument shipments and general availability of its tau and AKT1 assay kits targeted for mid-2027. Investors will be watching early access engagement, the conversion of early customers into commercial orders, and the pace at which additional oncology assays reach general availability.

On the financial side, the company's guidance that 2026 revenue will exceed its prior outlook of roughly $0.5 million provides a modest near-term benchmark, while single-digit full-year operating expense growth signals continued spending discipline. Cash runway, currently expected to extend into the first quarter of 2028, remains a key point of focus, particularly given the company's stated openness to raising capital ahead of the commercial ramp.

Broader industry dynamics also matter. Demand for high-resolution proteomics tools in drug discovery, biomarker research, and AI-driven biomedicine could support adoption, but the company must demonstrate that its reproducibility and throughput advantages translate into durable commercial traction. Progress on the SEEDS consortium, the Michael J. Fox Foundation collaboration, and publication-driven validation of the Iterative Mapping method will all serve as important signals of scientific and commercial momentum in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations